Therapeutic Efficacy of Cintredekin Besudotox (IL13-PE38QQR) in Murine Lung Fibrosis Is Unaffected by Immunity to Pseudomonas aeruginosa Exotoxin A


Autoria(s): ROSADA, Rogerio S.; MOREIRA, Ana P.; FRANTZ, Fabiani G.; PURI, Raj K.; RAHMAN, Aquilur; STANDIFORD, Theodore J.; ZARATE-BLADES, Carlos R.; SILVA, Celio L.; HOGABOAM, Cory M.
Contribuinte(s)

UNIVERSIDADE DE SÃO PAULO

Data(s)

17/04/2012

17/04/2012

2010

Resumo

Background: We have previously explored a therapeutic strategy for specifically targeting the profibrotic activity of IL-13 during experimental pulmonary fibrosis using a fusion protein comprised of human IL-13 and a mutated form of Pseudomonas aeruginosa exotoxin A (IL13-PE) and observed that the intranasal delivery of IL13-PE reduced bleomycin-induced pulmonary fibrosis through its elimination of IL-13-responsive cells in the lung. The aim of the present study was to determine whether the presence of an immune response to P. aeruginosa and/or its exotoxin A (PE) would diminish the anti-fibrotic properties of IL13-PE. Methodology/Principal Findings: Fourteen days after P. aeruginosa infection, C57BL/6 mice were injected with bleomycin via the intratracheal route. Other groups of mice received 4 doses of saline or IL13-PE by either intranasal or intraperitoneal application, and were challenged i.t. with bleomycin 28 days later. At day 21 after bleomycin, all mice received either saline vehicle or IL13-PE by the intranasal route and histopatological analyses of whole lung samples were performed at day 28 after bleomycin. Intrapulmonary P. aeruginosa infection promoted a neutralizing IgG2A and IgA antibody response in BALF and serum. Surprisingly, histological analysis showed that a prior P. aeruginosa infection attenuated the development of bleomycin-induced pulmonary fibrosis, which was modestly further attenuated by the intranasal administration of IL13-PE. Although prior intranasal administration of IL13-PE failed to elicit an antibody response, the systemic administration of IL13-PE induced a strong neutralizing antibody response. However, the prior systemic sensitization of mice with IL13-PE did not inhibit the anti-fibrotic effect of IL13-PE in fibrotic mice. Conclusions: Thus, IL13-PE therapy in pulmonary fibrosis works regardless of the presence of a humoral immune response to Pseudomonas exotoxin A. Interestingly, a prior infection with P. aeruginosa markedly attenuated the pulmonary fibrotic response suggesting that the immune elicitation by this pathogen exerts anti-fibrotic effects.

National Institutes of Health (NIH)

Fundacao de Amparo a Pesquisa do Estado de Sao Paulo (FAPESP)

NeoPharm, Inc

Identificador

PLOS ONE, v.5, n.1, 2010

1932-6203

http://producao.usp.br/handle/BDPI/14888

10.1371/journal.pone.0008721

http://dx.doi.org/10.1371/journal.pone.0008721

Idioma(s)

eng

Publicador

PUBLIC LIBRARY SCIENCE

Relação

Plos One

Direitos

openAccess

Copyright PUBLIC LIBRARY SCIENCE

Palavras-Chave #INDUCED PULMONARY-FIBROSIS #PARACOCCIDIOIDES-BRASILIENSIS CONIDIA #ALLERGIC AIRWAY DISEASE #RECEPTOR ALPHA-2 CHAIN #IL-13 RECEPTOR #INTERLEUKIN-13 RECEPTOR #CHIMERIC PROTEIN #CARCINOMA-CELLS #PERIBRONCHIAL FIBROSIS #SIGNAL-TRANSDUCTION #Biology #Multidisciplinary Sciences
Tipo

article

original article

publishedVersion